Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIPS: MMR Immunity and Booster Study in Adults
NCT05894395Phase 3Recruiting
- Sponsor
- University of Zurich
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of M-M-R II in measles, mumps and rubella (2 arms), sponsored by University of Zurich. Primary endpoint: Immunogenicity post MMR-booster vaccination at 1 year. Started Dec 2023; status: recruiting.
02
Drugs
M-M-R II
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on NCT05894395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894395.